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MDTs are also called as orally disintegrating tablets, 
orodispersible tablets, fast dissolving tablets, rapid 
dissolving tablets, rapid disintegrating tablets, porous 
tablets and rapi melts.1 Oral route is most preferred route 
by medical practitioners and manufacturer due to highest 
acceptability of patients.2 Oral routes of drug 
administration have world wide acceptance up to 50-60% 
of total dosage forms.3 However, tablets are most favorite 
and popular among the currently used dosage forms and 
efficacy of these dosage forms have been clinically 
evaluated because of its convenience in terms of self 
medication, compactness, ease in manufacturing, pain 
avoidance, and versatility.4-7 It has been reported that 
Dysphagia (difficulty in swallowing) is common among all 
age groups and more specific with pediatric, geriatric 
population along with institutionalized patients and 
patients with nausea, vomiting, and motion sickness 
complications.8,9 To avert the problems associated with 
conventional dosage forms, MDTs have been developed, 
which combine hardness, dosage uniformity, stability and 
other parameters, with extremely easy administration, 
since no water is required for swallowing the tablets and 
they are thus suitable for geriatric, pediatric and travelling 
patients.10-13 For these reason, scientists have developed 
the innovative concept of Mouth Dissolving Drug Delivery 
System (MDDDS) emerged from the desire to provide 
patient with more conventional means of taking their 
medications. MDDDS have started gaining popularity and 
acceptance as new drug delivery systems. These tablets 
disintegrate into smaller granules or melts in the mouth 
from a hard solid to a gel like structure, allowing easy 
swallowing by patients. The disintegration time for good 
MDTs varies from several seconds to about a minute.14 
United States Food and Drug Administration(US FDA) 
defined MDTs as “A solid dosage form containing 
medicinal substance or active pharmaceutical 
ingredients(API) which disintegrates rapidly usually within 
seconds when placed upon the tongue15.  
The basic approach in development of MDT is the use of 
superdisintegrants like crospovidone, croscarmellose 
sodium (Ac-Di-Sol), sodium starch glycolate etc. as 
synthetic superdisintegrants in the formulation of MDTs, 
which provide instantaneous disintegration of tablet after 
keeping on tongue, their by release the drug in saliva.16 
The proper selection of disintegrant or superdisintegrant 
and its consistency of performance are of critical 
importance in formulation development of such tablets.17 
Various technologies used for manufacturing MDTs 
include freeze drying, spray drying, tablet molding, 
sublimation, direct compression, sugar-based excipients, 
and disintegrant addition.18 Recent market studies indicate 
that ore than half of the patient population prefer MDTs to 
other dosage forms such as regular tablets or liquids 
(>80%).19] Furthermore, market size and popularity of 
these dosage forms will surely expand in future. This 
article is emphasized on the in-vivo and in-vitro evaluation 
of MDTs along with ideal properties, significance, and 
limitations of MDTs. 
IDEAL CHARACTERISTICS OF MDTS  
MDTs have several ideal characteristics to distinguish 
them from the more traditional dosage forms.[20-28] These 
tablets should: 
 Not require water or other liquid to swallow. 
 Give good mouth feel. 
 Easily Dissolve/Disperse/Disintegrate in saliva within 
few seconds. 
 Have a satisfactory taste masking properties. 
 Cost effectiveness. 
 Show signs of low sensitivity to environmental 
conditions like temperature, humidity etc.  
 Be harder and less friable. 
  Leave minimal or no residue in mouth after 
administration. 
 Allow the manufacture of tablet using conventional 
processing and packaging equipments. 
ABSTRACT 
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 Allow high drug loading. 
 Be portable without fragility concerns. 
SIGNIFICANCE OF MDTS  
MDTs offer all advantages of solid dosage forms and 
liquid dosage forms along with special advantages1,29-42 
which include: 
 Improved compliance/added convenience. 
 Achieve increased bioavailability/rapid absorption 
through pregastric absorption of drugs from mouth, 
pharynx and oesophagus as saliva passes down. 
 Rapid drug therapy intervention. 
 Good mouth feel property helps to change the 
perception of medication as “bitter pill” particularly in 
pediatric patients. 
 Risk of chocking or suffocation during oral 
administration is avoided, thus providing improved 
safety. 
 No water needed. 
 No chewing needed. 
 Improved stability. 
 No special set up required for the industry. 
 Rapid onset of action. 
 Lower doses. 
 New business opportunities like product 
differentiation, line extension, and life-cycle 
management, exclusivity of product promotion and 
patent-life extension. 
 Accurate dosing. 
 Small packaging size. 
LIMITATIONS OF MDTS  
The factors responsible for limiting their use vary from 
formulation till the effect of drug in the body.10,43-45 These 
are: 
 MDTs usually have inadequate mechanical strength. 
Hence, vigilant handling is required during 
formulation process. 
 The tablets may leave disagreeable taste and/or 
grittiness in mouth if not formulated appropriately. 
 Drugs with larger doses are difficult to formulate into 
MDTs e.g. Rifampin (600mg), ethambutol (1000mg) 
etc. 
 Taste masking is required. 
 Proteinaceous drugs should be avoided, if co-
administration of enzyme inhibitors such as aprotinin, 
bestatin, puromicin and bile salts are required for the 
inhibition of proteolytic enzymes present in saliva. 
 Patients who concomitantly take anticholinergic 
medication may not be the best candidates for MDTs 
and patients like Sjogren‟s syndrome or dryness of the 
mouth due to decrease saliva production may not be 
good candidates for these tablet formulation. 
IN-VITRO CHARACTERIZATION OF MDTS  
Enormous work has been done in this field, wherein some 
of the researchers have developed their own methods of 
evaluation. In the recent past, several new advanced 
technologies have been introduced for the formulation of 
MDTs. To ensure drug release from MDTs, the dosage 
form requires thorough and meticulous evaluation for 
optimum performance, which can be assessed indirectly by 
in-vitro technologies. 
Evaluation of tablets  
Evaluation parameters of tablets mentioned in the 
pharmacopoeias used to be assessed, along with some 
special tests are discussed.33 These include: organoleptic 
evaluation, weight variation, thickness, hardness, friability, 
wetting time, water absorption ratio, in-vitro disintegration 
test, drug content uniformity, swelling index, in-vitro drug 
release studies and moisture uptake studies. 
Organoleptic properties  
This is essential step in case of most oral formulation due 
to more residence time in the oral cavity. General 
appearance of a tablet, its visual identity and over all 
“elegance” is essential for consumer acceptance. Include in 
are tablet‟s size, shape, colour, presence or absence of an 
odour, taste, surface texture, physical flaws and 
consistency and legibility of any identifying marking.24,34,48 
In-vitro methods of utilizing taste sensors, specially 
designed apparatus and drug release by modified 
pharmacopoeial methods are being used for this purpose. 
Experiments using electronic tongue measurements are 
reported to distinguish between the sweetness levels in 
taste-masking formulation.   
Weight variation  
Twenty tablets are selected at a random from each 
formulation and average weight is determined. Then 
individual tablets are weighed using digital electronic 
balance and the individual weight is compared with the 
average weight. The mean ± SD (standard deviation) 
values are calculated.49 The weight variation test would be 
a satisfactory method of assessing the drug content 
uniformity. 
Thickness  
Tablet thickness is an important characteristic in 
reproducing appearance and also in counting. Three tablets 
are taken randomly from each formulation and their 
thickness is measured with Vernier caliper. The mean ± 
SD values are calculated.34,49 
Hardness  
Hardness of the tablet is defined as the force applied across 
the diameter of the tablet in order to break the tablet. 
Hardness of the tablets is measured using Pfizer type 
hardness tester. Three tablets are selected from each 
formulation randomly and their hardness is measured. The 
resistance of the tablet to abrasion, chipping or breakage 
under conditions of storage and handling before usage 
depends on its hardness. The mean ± SD of hardness 
values are calculated. It is expressed in Kg/pound.50,51 
Friability  
Friability of the tablets is determined using Roche 
friabilator. This device subjects a number of tablets to the 
combined effect of abrasions and shock in a plastic 
chamber revolving at 25 rpm and dropping the tablets at 
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distance of six inches with each revolution. Preweighed 
sample of tablets is placed in the fribilator and are 
subjected to 100 revolutions.52,53 Tablets are then de-
dusted and reweighed and percentage of weight loss is 




×100   
Wetting time  
Wetting time of dosage form is related to the contact angle. 
It needs to be assessed to give an insight into the 
disintegration properties of the tablets; a lower wetting 
time implies a quicker disintegration of the tablet. For this 
purpose, a piece of tissue paper folded twice is placed in a 
small petridish (i.d. 6.5 cm) containing 6 ml of water. A 
tablet is kept on the paper nd the time for complete wetting 
is measured. The mean ± SD values are calculated.54,19 
Water absorption ratio  
The weight of the tablet prior to placement in the petridish 
is noted (wb) utilizing a digital balance. The wetted tablet 
is removed and reweighed (wa). Water absorption ratio, R 
is then determined according to the following equation: 
R = 100× (wa - wb) / wb 
Where, wb and wa are tablet weights before and after water 
absorption, respectively. The mean ± SD values are 
calculated.49,55,56 
In vitro disintegration test  
Disintegration time is very important for MDTs which is 
desired to be less than 60 seconds for MDTs. This rapid 
disintegration assists swallowing of the tablet and also 
plays a role in drug absorption in buccal cavity, thus 
promoting bioavailability. In-vitro disintegration time is 
determined using disintegration test apparatus (Electrolab, 
USP model ED-2L) without disk for six tablets. The 
disintegration medium is 900 ml of distilled water kept at 
37 ± 0.5ºC and stirred at a rate of 30 ± 2 cycles/min. The 
time is measured in seconds for complete disintegration of 
the tablet with no palpable mass remaining in the 
apparatus. The test is carried out in triplicate.57,58 
Drug content uniformity  
This is determined by any standard assay method 
described for the particular API in any of the standard 
pharmacopoeia. Content uniformity is determined by 
estimating the API content in individual dosage form.1 
Limit of content uniformity is 85-115%. 
Swelling index  
The swelling index is the volume in milliliters occupied by 
1 gram of a superdisintegrant, including any adhering 
superdisintegrant, after it is swollen in an aqueous liquid 
for 4 h. In a 25 ml ground-glass stoppered cylinder 
graduated over a height of 125 ± 5 mm in 0.5 ml divisions, 
1.0 g of superdisintegrant is placed. Unless otherwise 
directed, the superdisintegrant is moistened with 1.0 ml of 
alcohol, 25 ml water is added and close the cylinder. The 
cylinder is shaken vigorously every 10 min for 1 h. It is 
allowed to stand for 3 h. At 90 min after the beginning of 
the test, any large volume of liquid retained in the layer of 
the superdisintegrant and any particle of superdisintegrant 
floating at the surface of liquid is released by rotating the 
cylinder about a vertical axis. The volume occupied by the 
superdisintegrant is measured, including any adhering 
mucilage. Three tests are carried out at the same time. The 
swelling index is calculated by the means of three 
tests.16,59,60 
In-Vitro drug release studies  
The expansion of dissolution methods for MDTs is 
comparable to the approach taken for conventional tablets, 
and is practically indistinguishable. Media such as 0.1N 
HCL and buffers (ph – 4.5 and 6.8) should be evaluated for 
MDT much in the same way as their ordinary tablet 
counter parts. The USP 2 Paddle apparatus is used for this 
purpose which is the most suitable and common choice for 
MDTs, with a paddle speed of 50 rpm commonly used.61 
Typically the dissolution of MDT is very fast when using 
USP monograph conditions; hence slower paddle speeds 
may be utilized to attain a profile. The USP 1 Basket 
apparatus may have certain applications but sometimes 
tablet fragments or disintegrated tablet masses may 
become trapped on the inside top of the basket at the 
spindle where little or no effective stirring occurs, yielding 
irreproducible dissolution profiles. 
Moisture uptake studies  
This parameter should be conducted for MDTs to assess 
the stability of the dosage form. Ten tablets from each 
batch are kept in a desiccator over calcium chloride at 
370C for 24h. The tablets are weighed and exposed to 75% 
relative humidity, at room temperature for 2 weeks. 
Required humidity is attained by keeping saturated sodium 
chloride solution at the bottom of the desiccator for 3 days. 
One tablet as control (without superdisintegrants) is kept to 
check the moisture uptake by the other excipients. Tablets 
are weighed and the percentage increase in the weight is 
recorded. If the moisture uptake tendency of a weighed 
tablet is high, it requires special dehumidified area for 
manufacturing and packaging.44,62-65 The materials with 
high moisture resistant properties should be used for 
packaging for e.g. alu strip pack, alu-alu blister or 
polyethylene sealing on blister. The use of appropriate 
quantity of desiccant in High density polyethylene bottle 
packs with minimum head space is highly recommended to 
ensure stability of the product during its shelf life.  
 IN-VIVO CHARACTERIZATION OF MDTS  
In-vivo studies exhibit the actual action of MDT in the 
oral-oesophageal tract, their pharmacokinetic and 
therapeutic efficacy, and acceptability. In-vivo test for the 
determination of disintegration time of MDTs can be 
conducted on volunteers who are usually randomized to 
receive the treatments and then directed to clean their 
mouth with water. Tablets are placed on their tongues, and 
the time for disintegration is measured by immediately 
starting a stopwatch. Immediately after the last noticeable 
granule has disintegrated, the stopwatch is stopped and the 
time recorded.66-68 In-vivo taste evaluation consists of a 
double blind crossover study, carried out on a trained panel 
of healthy volunteers with their prior assent. On keeping 
the dosage form in the oral cavity, the disintegration time 
is noted after which it is further held in mouth for 60 sec 
by each volunteer, and the bitterness level is noted down 
against pure drug (control) using a numerical scale. The 
numerical scale bears the following value: 0 = tasteless, 
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0.5 = after taste, 1.0 = slight, 1.5 = slight to moderate, 2.0 
= moderate, 2.5 = moderate to strong, 3 = strong and 3+ = 
very strong. A few examples are illustrated below, 
showing the work of various scientists in the field of in-
vivo evaluation. 
Panizo C et al., (2010) studied in-vivo immunological 
changes induced by a short course of grass Allergy 
Immunotherapy Tablets (AIT). They performed a 
randomized, double-blind placebo-controlled trial with 78 
patients randomly assigned to receive either grass AIT or 
placebo in a 2:1 ratio and found that treatment with grass 
AIT for grass pollen allergic rhinoconjunctivitis induces 
immunological changes after only 1 month of treatment.69 
Visser MR et al., (2010) adopted Inulin solid dispersion 
technology to improve the absorption of the BCS class IV 
drug TMC240. Single-dose study in dogs (200mg of 
TMC240), plasma concentrations of TMC240 remained 
below the lower limit of quantification (<1.00ng/mL) in all 
animals (n=3 per tested formulation), except in one dog 
receiving the inulin solid dispersion tablet [C (max) 
=1.8ng/mL, AUC (0-7h) =3.0ngh/mL]. The current data 
demonstrate that a solid dispersion of TMC240 in an inulin 
matrix allows considerable improvement in the release of 
poorly water-soluble TMC240, both in-vitro in the 
presence of a surfactant and in-vivo upon oral 
administration.70 Indumathi D et al., (2010) investigated 
in-vivo release studies of fluxetine fast dissolving tablet as 
control formulation and test formulation using rabbit as 
animal model. The plasma samples were separated by 
centrifugation and the drug was extracted. Then the 
samples were assayed by high performance liquid 
chromatography.71 They found that in-vivo drug release 
studies of test formulation were found to be better than that 
of control formulation. Gupta AK et al., (2011) carried 
out in-vivo mouth disintegration test for determination of 
disintegration time in saliva. They found that with 
increases in camphor ratio, tablet disintegrates rapidly in 
the saliva, which may be related to an improvement of the 
water penetration into the tablets due to high porosity.72 
CONCLUSION 
With the increase demand of novel drug delivery, the 
MDDDS has become one of the major mile stone of 
current investigations. This article attempts to present a 
detailed review regarding technological advances made so 
far in the area of evaluation of MDTs with respect to 
special characteristics of these inimitable dosage forms. 
Encouraging results of in-vivo evaluation revealed that in 
future, MDT may be most acceptable and prescribed 
dosage form due to its immediate action (within minute). 
Their characteristic advantages such as administration 
without water, anywhere, anytime lead to their increased 
patient compliance in today‟s scenario of hectic life.
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